サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1799158

がん治療における新規ドラッグデリバリーシステムの世界市場

Novel Drug Delivery Systems in Cancer Therapy

出版日
ページ情報
英文 181 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円
がん治療における新規ドラッグデリバリーシステムの世界市場
出版日: 2025年08月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 181 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

がん治療における新規ドラッグデリバリーシステムの世界市場は2030年までに米国で645億米ドルに達する見込み

2024年に213億米ドルと推定されるがん治療における新規ドラッグデリバリーシステムの世界市場は、分析期間2024-2030年にCAGR 20.3%で成長し、2030年には645億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるナノ粒子は、CAGR18.0％を記録し、分析期間終了時には358億米ドルに達すると予測されます。塞栓用粒子セグメントの成長率は、分析期間中CAGR23.6％と推定されます。

米国市場は58億米ドルと推定、中国はCAGR26.9%で成長予測

米国のがん治療における新規ドラッグデリバリーシステム市場は、2024年に58億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに150億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは26.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ16.4%と18.0%と予測されています。欧州では、ドイツがCAGR約16.9%で成長すると予測されています。

世界のがん治療における新規ドラッグデリバリーシステム- 主要動向と促進要因のまとめ

なぜ従来のがん治療が新しいドラッグデリバリーシステムによって破壊されるのか？

従来の化学療法は、全身毒性、生物学的利用能の低さ、腫瘍特異性の欠如といった、治療効果と患者のQOLを損なう問題に長い間悩まされてきました。新規ドラッグデリバリーシステム（NDDS）は、健康な組織へのダメージを最小限に抑えながら、腫瘍部位に直接抗がん剤の標的送達を提供するもので、腫瘍学の変革技術として急速に台頭してきています。薬物動態を向上させ、薬剤耐性メカニズムを克服することで、NDDSは臨床医が複雑で不均一ながん種にアプローチする方法を再定義しています。

最も重要な技術革新は、リポソーム、デンドリマー、ミセル、ポリマーナノ粒子などのナノキャリアであり、これらは細胞毒性薬剤をカプセル化し、腫瘍微小環境での制御放出を可能にします。これらのシステムは、固形腫瘍で観察される透過性・滞留性の向上（EPR）効果を利用して、部位特異的なデリバリーを実現します。その結果、高い治療効果が得られ、標的外毒性も軽減されます。さらに、抗体、ペプチド、アプタマーなどのリガンドを用いたコンジュゲート・システムが開発されており、HER2、EGFR、CD44などのがん特異的受容体を積極的に標的とすることで、個別化・精密がん治療戦略を可能にしています。

新たなテクノロジーは、がんドラッグデリバリーの能力をどのように拡大しているのか？

技術的収束は、がん領域におけるNDDSの範囲と有効性を急速に高めています。pH、温度、酵素、酸化還元勾配などの刺激に反応するスマートなナノ粒子は、腫瘍の微小環境に合わせたオンデマンドの薬物放出を可能にしています。例えばpH感受性のリポソームは、循環中では安定であるが、腫瘍の酸性環境ではペイロードを放出します。磁気誘導薬物キャリアや超音波トリガーナノバブルも、最小限の侵襲で局所にデリバリーするために研究中です。

もう一つのフロンティアは、イメージング機能とドラッグデリバリーの統合で、診断と治療を一つのシステムで行うセラノスティック・プラットフォームにつながります。このようなシステムでは、薬物の分布や腫瘍の反応をリアルタイムでモニターできるため、適応に応じた治療レジメンが可能になります。さらに、幹細胞や樹状細胞に由来するエクソソームベースのデリバリー・プラットフォームは、その生来の生体適合性と免疫検出を回避する能力から、薬物輸送にステルスのようなアプローチを提供するものとして研究されています。

生分解性ハイドロゲル、移植可能なリザーバー、吸入可能なナノ粒子は、静脈内投与にとどまらず、送達経路を拡大しつつあります。これらのシステムは患者のコンプライアンスを向上させ、膠芽腫、膵臓がん、大腸がんなどの固形がんに対する局所的な徐放性製剤を可能にします。COVID-19ワクチンによって普及したmRNA搭載脂質ナノ粒子は現在、腫瘍特異的抗原を送達しT細胞応答を刺激するがん免疫療法に再利用されつつあります。

NDDSの採用をリードしているがんの種類と治療法は？

乳がん、肺がん、卵巣がん、膵臓がんなどの固形がんは、その明確な微小環境と確立された分子標的により、NDDS統合の最前線にあります。リポソーム型ドキソルビシン（ドキシルなど）やアルブミン結合型パクリタキセル（アブラキサン）は、従来の化学療法と比較して安全性と無増悪生存期間の改善を示したNDDSの商業的成功例です。アドトラスツズマブ・エムタンシン（カドサイラ）のようなHER2標的抗体薬物複合体（ADC）は、受容体結合と細胞内細胞毒性による二重作用で、HER2陽性乳がんの治療に革命をもたらしています。

白血病やリンパ腫のような血液悪性腫瘍も、ナノ粒子カプセル化薬剤や標的タンパク質分解剤の恩恵を受けています。CAR-T細胞療法や免疫チェックポイント阻害剤は、腫瘍関連マクロファージを調節したり、免疫抑制遺伝子をダウンレギュレートするsiRNAを送達するために、NDDSによるサポートがますます増えています。研究は転移性がんや薬剤耐性がんにおいて特に盛んで、多剤併用ナノ粒子システムは、排出ポンプや腫瘍の不均一性を克服するために設計されています。

地域的には、米国がFDAの承認と国立がん研究所の資金援助に支えられ、臨床試験活動でも商業展開でもリードしています。欧州は、精密医療への取り組みに対する強力な規制の後ろ盾でこれに続きます。アジア太平洋では、中国、日本、韓国のような国々が、ナノメディシンの新興企業や製造インフラに多額の投資を行い、地域のイノベーションと世界市場への参入を加速させています。

がん治療におけるNDDSの世界市場の成長を促進しているものは何か？

がん治療用新規ドラッグデリバリーシステムの世界市場の成長は、がん罹患率の上昇、がん治療薬パイプラインの拡大、標的治療を支持する臨床エビデンスの増加など、いくつかの要因によって牽引されています。低侵襲で個別化された治療オプションに対する需要の高まりが、現代の腫瘍学の目標に合致した高度な送達プラットフォームへの投資を促進しています。

製薬会社はNDDSを活用し、薬剤の改良による特許期間の延長、新たな適応症への参入、混雑した治療環境におけるパイプラインの差別化を図っています。バイオテクノロジー新興企業、学術研究所、製薬大手間の戦略的提携は、研究室規模のイノベーションから臨床・商業展開へのトランスレーショナル・ジャーニーを加速させています。規制当局もまた、画期的治療薬や早期承認経路の下でNDDSを承認することで、柔軟性を示しています。

さらに、アウトカムベースのモデルに対する支払者の関心は、高コストだが高い有効性を持つNDDS療法に有利な償還環境を作り出しています。データ分析とデジタルバイオマーカーが患者の層別化を改善するにつれて、これらのシステムは精密腫瘍学の基礎となります。材料科学、生物工学、AIを活用した薬剤最適化の治療により、がん治療におけるNDDS市場は、複数の腫瘍タイプ、治療環境、地域にわたって力強く拡大する態勢が整っています。

セグメント

製品タイプ（ナノ粒子、塞栓粒子）

調査対象企業の例

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Becton, Dickinson and Co.
  • BioNTech SE
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Celsion Corporation
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • ImmunoGen, Inc.
  • Ipsen
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP39108

Global Novel Drug Delivery Systems in Cancer Therapy Market to Reach US$64.5 Billion by 2030

The global market for Novel Drug Delivery Systems in Cancer Therapy estimated at US$21.3 Billion in the year 2024, is expected to reach US$64.5 Billion by 2030, growing at a CAGR of 20.3% over the analysis period 2024-2030. Nanoparticles, one of the segments analyzed in the report, is expected to record a 18.0% CAGR and reach US$35.8 Billion by the end of the analysis period. Growth in the Embolization Particles segment is estimated at 23.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.8 Billion While China is Forecast to Grow at 26.9% CAGR

The Novel Drug Delivery Systems in Cancer Therapy market in the U.S. is estimated at US$5.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$15.0 Billion by the year 2030 trailing a CAGR of 26.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.4% and 18.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 16.9% CAGR.

Global Novel Drug Delivery Systems in Cancer Therapy - Key Trends & Drivers Summarized

Why Are Traditional Cancer Treatments Being Disrupted by Novel Drug Delivery Systems?

Conventional chemotherapy has long been plagued by systemic toxicity, poor bioavailability, and lack of tumor specificity-issues that compromise treatment efficacy and patient quality of life. Novel drug delivery systems (NDDS) are rapidly emerging as transformative technologies in oncology, offering targeted delivery of anticancer agents directly to tumor sites while minimizing damage to healthy tissues. By enhancing pharmacokinetics and overcoming drug resistance mechanisms, NDDS have redefined how clinicians approach complex and heterogeneous cancer types.

Among the most significant innovations are nanocarriers such as liposomes, dendrimers, micelles, and polymeric nanoparticles, which encapsulate cytotoxic agents and enable controlled release at the tumor microenvironment. These systems exploit the Enhanced Permeability and Retention (EPR) effect observed in solid tumors to achieve site-specific delivery. The result is a higher therapeutic index and reduced off-target toxicity. Additionally, conjugated systems using ligands such as antibodies, peptides, or aptamers are being developed to achieve active targeting of cancer-specific receptors like HER2, EGFR, and CD44, thereby enabling personalized and precision oncology strategies.

How Are Emerging Technologies Expanding Capabilities in Cancer Drug Delivery?

Technological convergence is rapidly enhancing the scope and efficacy of NDDS in oncology. Smart nanoparticles that respond to stimuli such as pH, temperature, enzymes, or redox gradients are enabling on-demand drug release, tailored to the tumor’s microenvironment. pH-sensitive liposomes, for instance, remain stable in circulation but release payloads in the acidic milieu of tumors. Magnetically guided drug carriers and ultrasound-triggered nanobubbles are also under investigation for localized delivery with minimal invasiveness.

Another frontier is the integration of imaging capabilities with drug delivery, leading to theranostic platforms that combine diagnosis and therapy in a single system. These systems allow for real-time monitoring of drug distribution and tumor response, enabling adaptive treatment regimens. Additionally, exosome-based delivery platforms derived from stem cells or dendritic cells are being explored for their innate biocompatibility and ability to bypass immune detection, providing a stealth-like approach to drug transport.

Biodegradable hydrogels, implantable reservoirs, and inhalable nanoparticles are extending delivery routes beyond intravenous administration. These systems improve patient compliance and enable localized, sustained-release formulations for solid tumors such as glioblastoma, pancreatic, and colorectal cancers. mRNA-loaded lipid nanoparticles, popularized by COVID-19 vaccines, are now being repurposed for cancer immunotherapy to deliver tumor-specific antigens and stimulate T-cell responses.

Which Cancer Types and Therapies Are Leading Adoption of NDDS?

Solid tumors such as breast, lung, ovarian, and pancreatic cancers are at the forefront of NDDS integration due to their well-defined microenvironments and established molecular targets. Liposomal doxorubicin (e.g., Doxil) and albumin-bound paclitaxel (Abraxane) are commercially successful examples of NDDS that have demonstrated improved safety and progression-free survival compared to traditional chemotherapies. HER2-targeted antibody-drug conjugates (ADCs), such as ado-trastuzumab emtansine (Kadcyla), are revolutionizing treatment for HER2-positive breast cancer, offering dual action through receptor binding and intracellular cytotoxicity.

Hematological malignancies like leukemia and lymphoma are also benefiting from nanoparticle-encapsulated drugs and targeted protein degraders. CAR-T cell therapy and immune checkpoint inhibitors are increasingly being supported by NDDS to modulate tumor-associated macrophages or deliver siRNA that downregulates immunosuppressive genes. Research is particularly intense in metastatic and drug-resistant cancers, where multi-drug nanoparticle systems are being engineered to overcome efflux pumps and tumor heterogeneity.

Regionally, the United States leads in both clinical trial activity and commercial deployment, supported by FDA approvals and National Cancer Institute funding. Europe follows with strong regulatory backing for precision medicine initiatives. In Asia-Pacific, countries like China, Japan, and South Korea are investing heavily in nanomedicine startups and manufacturing infrastructure to accelerate local innovation and global market participation.

What Is Fueling Growth in the Global Market for NDDS in Cancer Therapy?

The growth in the global novel drug delivery systems market for cancer therapy is driven by several factors, including escalating cancer prevalence, expanding oncology drug pipelines, and increasing clinical evidence supporting targeted therapies. Rising demand for minimally invasive, personalized treatment options has catalyzed investment in advanced delivery platforms that align with modern oncology goals.

Pharmaceutical companies are leveraging NDDS to extend patent life through drug reformulation, enter new indications, and differentiate their pipelines in a crowded therapeutic landscape. Strategic collaborations between biotech startups, academic labs, and pharmaceutical giants are accelerating the translational journey from lab-scale innovation to clinical and commercial deployment. Regulatory agencies are also demonstrating flexibility by approving NDDS under breakthrough therapy and accelerated approval pathways.

Moreover, payer interest in outcomes-based models is creating a favorable reimbursement climate for high-cost but high-efficacy NDDS therapies. As data analytics and digital biomarkers improve patient stratification, these systems will become cornerstones of precision oncology. With advances in materials science, bioengineering, and AI-driven drug optimization, the NDDS market in cancer therapy is poised for robust expansion across multiple tumor types, treatment settings, and geographies.

SCOPE OF STUDY:

The report analyzes the Novel Drug Delivery Systems in Cancer Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Nanoparticles, Embolization Particles)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Becton, Dickinson and Co.
  • BioNTech SE
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Celsion Corporation
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • ImmunoGen, Inc.
  • Ipsen
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Novel Drug Delivery Systems in Cancer Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surging Oncology Pipeline Throws the Spotlight on Novel Drug Delivery Systems in Cancer Therapy
    • Limitations of Conventional Chemotherapy Propel Investment in Targeted Delivery Innovations
    • Advances in Nanotechnology and Lipid Nanoparticles Accelerate Growth in Next-Gen Platforms
    • Rising Adoption of Immuno-Oncology and mRNA-Based Therapies Drives Development of Specialized Carriers
    • Collaboration With Biopharma Innovators Strengthens Commercialization of Delivery Technologies
    • Regulatory Approvals for Injectable Depot Systems Expand Use in Long-Term Cancer Management
    • Surge in Precision Medicine Initiatives Spurs Use of Patient-Specific Drug Delivery Systems
    • Tumor Microenvironment Research Accelerates Innovation in Site-Specific Delivery Vectors
    • Integration of pH-Responsive and Thermosensitive Materials Enhances Delivery Accuracy
    • Biodegradable Polymers and Carrier Systems Gain Traction for Controlled Release Applications
    • Expansion of Companion Diagnostics Market Enables Alignment With Delivery-Optimized Formulations
    • Development of Smart Capsules and Microneedle Arrays Supports Non-Invasive Delivery Modes
    • Growth in Oncology Trials Utilizing Nano-Carriers Propels Technological Validation
    • Partnerships With CDMOs Fuel Scale-Up and GMP Manufacturing of Novel Delivery Modalities
    • Government Funding for Next-Generation Oncology Platforms Strengthens Industry R&D
    • Patient Demand for Reduced Side Effects and Enhanced QoL Drives Preference for Targeted Delivery
    • Focus on Drug-Device Combination Products Expands Integration Across Multiple Delivery Routes
    • Rise in Orphan Cancer Drug Development Spurs Innovation in Niche Delivery Systems
    • Market Differentiation Strategies Among Pharma Players Fuel Investment in Novel Carriers
    • Shift Toward Outpatient Oncology Treatment Models Propels Demand for Sustained Release Formulations
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Novel Drug Delivery Systems in Cancer Therapy Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Nanoparticles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Nanoparticles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Nanoparticles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Embolization Particles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Embolization Particles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Embolization Particles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • JAPAN
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • CHINA
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: China 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • EUROPE
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • FRANCE
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: France 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • GERMANY
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • INDIA
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: India 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • AFRICA
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030

IV. COMPETITION